European Women’s Health M&A Reached Two-Decade High
Pharma and consumer health firms are aggressively acquiring specialty assets to capture demand.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Should healthcare investors prioritize funding for women's health companies to close existing research gaps?
European women's health M&A volume hit EUR 3.9 billion in the first nine months of 2026, marking a 20-year peak for the sector. Acquisitions are accelerating as companies look to expand portfolios into consumer-facing areas like telehealth and supplements.
Why it matters
Rising public awareness of conditions like menopause and a broader shift toward consumerized healthcare are forcing firms to scale their portfolios. These acquisitions allow established players to capture direct-to-consumer demand for specialized health products.
Transaction volume reached EUR 3.9 billion in the first nine months of 2026, significantly outpacing the EUR 71 million recorded in the same period of 2025. Notable activity included the EUR 873 million acquisition of Vitabiotics.
The players
Sun Pharma
A global specialty generic pharmaceutical company that pursues large-scale inorganic growth.
Apollo Global Management
A major alternative investment manager that deploys significant private capital into healthcare assets.
KKR
A leading global investment firm that actively partners with corporate entities to fund healthcare business units.
Procter & Gamble
A multinational consumer goods corporation that targets acquisitions to expand its footprint in the consumer health market.
Natural Cycles
A Swedish developer of digital health technology currently evaluating strategic IPO or sale options.
The details
Large pharmaceutical and consumer health companies are actively buying specialty firms and startups to modernize their product lines. This trend is driven by high interest in consumer health sectors, particularly in supplements and digital tools. Smaller firms are also seeing increased interest, evidenced by Evvy raising a USD 40 million Series B round and companies like Natural Cycles exploring strategic exits.
Timeline
2023 saw Otsuka acquire Bonafide Health for USD 425 million.
Endometriosis funding reached over USD 57 million in 2025, up from minor levels in 2024.
Strategic reviews were initiated at Wild Nutrition and Natural Cycles in January 2026.
European women's health deal volume peaked during the first nine months of 2026.
Market Landscape
This deal surge follows the ongoing consumerization of healthcare where companies are shifting toward direct-to-consumer models. The activity marks a significant departure from historical trends, as endometriosis funding and menopause-related products move from niche interests to core portfolio assets.
Operators in the healthcare space should prepare for heightened competition as legacy firms integrate newly acquired supplement and telehealth capabilities. Leaders should monitor strategic reviews at firms like Natural Cycles to identify the next wave of potential consolidation targets.
The takeaway
The women's health sector is rapidly evolving from a niche category to a high-priority investment area for global pharmaceutical giants. Executives should monitor the integration of these consumer-facing brands as a proxy for shifting retail demand in specialized health segments.
Further reading
For more on industry shifts, visit our Healthcare section.
Source note: This article includes information reported by ION Analytics.
Live Poll
Should healthcare investors prioritize funding for women's health companies to close existing research gaps?
